PLK4
Serine/threonine-protein kinase PLK4
As of the edition of 20 October 2026, PLK4 (serine/threonine-protein kinase PLK4, UniProt O00444) has 3 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O00444
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 19
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Urinary and reproductive
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ocifisertib | Active | Phase 2 | none listed |
| RG-1530 | Went quiet | Phase 1 | none listed |
| RP-1664 | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Xeno Biosciences | Route A |
| Roche | Route A |
The other 1 company at PLK4
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at PLK4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.